Hengrui Pharma (01276) surged over 6%. As of the time of writing, it rose by 6.15%, trading at HKD 63.9, with a turnover of HKD 113 million.
According to Zhitong Finance APP, Hengrui Pharma (01276) rose more than 6%. As of the time of writing, it was up 6.15%, trading at HKD 63.9 with a turnover of HKD 113 million.
In terms of developments, on March 4, Hengrui Pharma announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., had received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for HRS-1780 tablets, approving the commencement of clinical trials for the treatment of primary aldosteronism. Additionally, its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengrui Pharma Co., Ltd., received the 'Clinical Trial Approval Notice' from the National Medical Products Administration for SHR-A2102 for injection and SHR-8068 injection, respectively, and will commence clinical trials shortly.
